in early-stage choroidal melanoma. Bel-sar is from a novel class of virus-like drug conjugate therapies that Boston, Massachusetts-based Aura is developing for various oncology indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback